Nat2 gene polymorphism in bladder cancer: A study from North India

International Braz J Urol

Volumn 30, Issue 4, 2004, Pages 279-285

  Mittal, Rama D ^a   Srivastava, Daya S L ^a   Mandhani, Anil ^a  

^a SANJAY GANDHI POSTGRADUATE INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Arylamine N Acetyltransferase; Bladder neoplasms; Polymorphism genetics; Risk; Tobacco

Indexed keywords

ARYLAMINE ACETYLTRANSFERASE; GENOMIC DNA;

ARTICLE; BLADDER CANCER; BLOOD SAMPLING; CANCER RISK; CASE CONTROL STUDY; CIGARETTE SMOKING; CONFIDENCE INTERVAL; CONTROLLED STUDY; DATA ANALYSIS; FISHER EXACT TEST; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; INDIA; MAJOR CLINICAL STUDY; POLYMERASE CHAIN REACTION; POPULATION RESEARCH; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RISK ASSESSMENT; RISK FACTOR; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE;

EID: 4544265689     PISSN: 16775538     EISSN: None     Source Type: Journal    
DOI: 10.1590/S1677-55382004000400003     Document Type: Article

References (27)

1. Hein DW: Acetylator genotype and arylamine induced carcinogenesis. Biochem Biophys Acta. 1988; 948: 37-66.
2. Hein DW, Doll MA, Gray K, Rustan TD, Ferguson RJ: Metabolic activation of N-hydroxy-2-acetylaminofluorene by NAT1 and NAT2 in colon cytosols of Syrian hamster congenic at the NAT2 locus. Cancer Res. 1993; 53: 509-14.
3. Vatsis KP, Weber WW, Bell DA, Dupret JM, Evans DA, Grant DM, et al.: Nomenclature for N-acetyltransferase. Pharmacogenetics. 1995; 5: 1-17.
4. Ames BN, Durston WE, Yamasaki E, Lee FD: Carcinogens are mutagens: a simple test system combining liver homogenates for activation and bacteria for detection. Proc Natl Acad Sci. 1973; 70: 2281-5.
5. Miller EC: Some current perspectives on chemical carcinogenesis in humans and experimental animals. Cancer Res. 1978; 38: 1479-96.
6. Hein DW, Doll MA, Rustan TD, Gray K, Feng Y, Fergusan R, et al.: Metabolic activation and deactivation of arylamine carcinogens by recombinant human NAT1 and polymorphic NAT2 acetyltransferases. Carcinogenesis. 1993; 14: 1633-8.
7. Cascorbi I, Brockmoller J, Mrozikiewicz PM, Muller A, Roots I: Arylamines N-acetyltransferase activity in man. Drug Metab Rev. 1999; 31: 489-502.
8. Caporaso N, Goldstein A: Cancer genes: single and susceptibility: exposing the difference. Pharmacogenetics. 1995; 5: 59-63.
9. Silverman DT, Rothman N, Devesa SS: Epidemiology of Bladder Cancer In: KN Syrigos, DG Skinner (eds.), Bladder Cancer. Biology, Diagnosis, Management. Oxford University Press Inc., New York; pp. 11-55.
10. Wadelius JE, Autrup JL, Stubbins MJ, Andersson SO, Johanason JE, Wadelius C, et al.: Polymorphism in NAT2, CYP2D6, CYP2C19 and GSTP1 and their association in prostate cancer. Pharmacogenetics. 1999; 9: 333-40.
11. Guengerich FP: Influence of nutrients and dietary materials on Cytochrome P-450 enzymes. Am J Clin Nutr. 1995; 61: 651-58.
12. Hein DW, Doll MA, Fretland AJ, Leff MA, Webb SJ, Xiao GH, et al.: Molecular genetics and epidemiology of the NAT1 and NAT2 acetylation polymorphisms. Cancer Epidemiol Biomarkers Prev. 2000; 9: 29-42.
13. Turesky RJ, Lang NP, Butler MA,Teitel CH, Kadlubar FF. Metabolic activation of carcinogenic heterocyclic amines by human liver and colon. Carcinogenesis. 1991; 12: 1839-45.
14. Grant DM, Hughes NC, Janezic SA, Goodfellow GH, Chen HJ, Gaedigk A, et al.: Human acetyltransferase polymorphisms. Mutat Res. 1997; 376: 61-70.
15. Stern MC, Johnson LR, Bell DA, Taylor JA: XPD codon 751 polymorphism, metabolism genes, smoking, and bladder cancer risk. Cancer Epidemiol Biomarkers Prev. 2002; 11:1004-11.
16. Inatomi H, Katoh K, Kawamoto T, Matsumoto T: NAT2 gene polymorphism as a possible biomarker for susceptibility to bladder cancer in Japanese. Int J Urol.1999; 6: 446-54.
17. Hamasaki T, Inatomi H, Katoh K, Aono M, Ikuyama T,Muratani T, et al.: NAT2 gene polymorphism as a possible biomarker for susceptibility to prostate cancer in Japanese. Int J Urol. 1999; 6: 446-54. (Erratum in: Int J Urol 1999; 6: 592).
18. Lin HJ, Han C-Y, Lin BK, Hardy S: Ethnic distribution of slow acetylator mutation in the polymorphic N-acetyltransferase (NAT2) gene. Pharmacogenetics. 1994; 4: 125-34.
19. Xie HG, Xu ZH, Ou-Yang DS, Shu Y, Yang DL, Wang JS, et al.: Meta-analysis of phenotype and genotype of NAT2 deficiency in Chinese population. Pharmacogenetics. 1997; 7: 503-14.
20. Woolhouse NM, Qureshi MM, Bastaki SM, Patel M, Abdulrazzaq Y, Bayoumi RA: Polymorphic N-acetyltransferase (NAT2) genotyping of Emiratis. Pharmacogenetics.1997; 7: 73-82.
21. Anitha A, Banerjee M: Arylamine N-acetyltransferase 2 polymorphism in the ethnic population of South Indians. Int J Mol Med. 2003; 11: 125-31.
22. Sambrook J, Fritsch E, Maniatis T: Molecular Cloning - A Laboratory Manual, 2nd ed. New York, Cold Spring Harbor Laboratory Press. 1989.
23. Taylor JA, Umbach DM, Stephens E, Castranio T, Paulson D, Robertson C, et al.: The role of N-acetylation polymorphism in smoking-associated bladder cancer: evidence of a gene-gene-exposure three-way interaction. Cancer Res. 1998; 58: 3603-10.
24. Marcus PM, Hayes RB, Vineis P, Garcia-Closas M, Caporaso NE, Autrup H, et al.: Cigarettes smoking, N-acetyltransferase 2 acetylation status, and bladder cancer risk: a case series meta-analysis of gene-environmental interaction. Cancer Epidemiol Biomarkers Prev. 2000; 9: 461-7.
25. Marcus PM, Vineis P, Rothman N: NAT2 slow acetylation and bladder cancer risk: a meta-analysis of 22 case control studies conducted in general population. Pharmacogenetics. 2000; 10: 115-22.
26. Lang NP, Kadlubar FF: Aromatic and heterocyclic amine metabolism and phenotyping in humans. Prog Clin Biol Res. 1991; 372: 33-47.
27. Brockmoller J, Cascorbi I, Kerb R, Roots I: Combined analysis of inherited polymorphism in arylamine N-acetyltransferases M1 and T1, microsomal epoxide hydrolase, and CYP 450 enzyme as modulator of bladder cancer risk. Cancer Res. 1996; 56: 3915-25.